Abstract 3332: Engineering functions in cell transduction domains: novel anticancer agents

Abstract Trojantec research has focused on the design of recombinant proteins that overcome both extracellular and intracellular limitations of other delivery systems by rapidly releasing proteins into the cytoplasm and mediating efficient nuclear translocation. We have genetically engineered two fusion proteins; The first consisting of the Drosophila transcription factor Antennapedia (ANTP) and the truncated version of Mastermind-like (MAML) that behaves in a dominant negative (DN) fashion and inhibits Notch activation (ANTP/DN MAML) (TR4), and the second which is comprised of ANTP fused to the tumour suppressor protein p21, which is important in many key cell division processes including G1-arrest leading to apoptosis of damaged cells. Our results indicate that drug delivery using with the ANTP cell transduction domain induces apoptosis, abolishes colony formation in soft agar, and inhibits tumor growth in mice, without organ or systemic toxicity. These studies establish TR1 and TR4 as new cancer therapeutic agents in clinical applications. Note: This abstract was not presented at the AACR 101st Annual Meeting 2010 because the presenter was unable to attend. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3332.